Acurx initiated with a Buy at H.C. Wainwright

H.C. Wainwright analyst Ed Arce initiated coverage of Acurx with a Buy rating and $14 price target. Ibezapolstat’s dual activity "appears to consistently clear CDI rapidly and completely," Arce tells investors in a research note. Acurx is a clinical stage biopharmaceutical company focused on developing a new class of antibiotics for infections that have acquired antimicrobial resistance to existing therapies, says the analyst. He believes ibezapolstat demonstrates high concentrations in the colon, with virtually no systemic absorption.